Management of Hypercalcemia

Initial Assessment and Diagnostic Workup

A calcium level of 2.67 mmol/L (10.7 mg/dL) in a patient represents mild hypercalcemia that requires diagnostic evaluation and appropriate management based on the underlying cause, with a mild hypercalcemia range of >5.0 to <5.5 mEq/L or <12 mg/dL 1
Calculate corrected calcium using the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) - 0.8 × [Albumin (g/dL) - 4] to confirm true hypercalcemia 1
Evaluate for symptoms which may include fatigue, constipation, polyuria, polydipsia, nausea, and confusion in mild to moderate cases 1
Order first-line laboratory tests including serum albumin, intact parathyroid hormone (iPTH), serum creatinine, blood urea nitrogen, serum phosphorus, magnesium levels, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D levels to distinguish PTH-dependent from PTH-independent causes 2, 3
Check urine calcium/creatinine ratio to evaluate for hypercalciuria, and perform renal ultrasonography if hypercalciuria is present to evaluate for nephrocalcinosis 3

For mild asymptomatic hypercalcemia, increase oral hydration to enhance renal calcium excretion, avoid calcium supplements and foods with high calcium content, and avoid vitamin D supplements containing glucose-based sweeteners 1, 4
Maintain normal dietary calcium intake (not restricted) unless specifically indicated 5
For symptomatic or progressive hypercalcemia, provide intravenous hydration with normal saline, and consider bisphosphonate therapy (pamidronate or zoledronic acid) for severe or symptomatic hypercalcemia 5

In pediatric patients, hypercalcemia may be associated with Williams syndrome, which requires monitoring calcium levels every 4-6 months until 2 years of age, then every 2 years 3
For adolescents with hypercalcemia, treatment with a low-calcium diet and increased water intake under medical and nutritional supervision is often successful, and avoid multivitamin preparations containing vitamin D in early childhood 3
Avoid excessive vitamin D supplementation which can worsen hypercalcemia, and do not administer phosphate supplements together with calcium supplements or foods with high calcium content 3, 4

Monitor serum calcium, renal function, and electrolytes regularly to assess treatment effectiveness, and perform periodic assessment of bone mineral density as approximately 50% of individuals with hypercalcemia may have impaired bone mineral status (osteopenia or osteoporosis) 3, 5
For patients requiring bisphosphonate therapy, monitor for potential complications including renal toxicity and hypocalcemia post-treatment 1

Check urine calcium/creatinine ratio to evaluate for hypercalciuria, and consider renal ultrasonography if hypercalciuria is present to evaluate for nephrocalcinosis, as recommended by the American Academy of Pediatrics 6

For symptomatic or moderate hypercalcemia, consider loop diuretics only after adequate hydration is achieved, particularly in patients with heart failure or renal insufficiency, as suggested by the American Heart Association 7
For severe hypercalcemia or symptomatic cases, administer bisphosphonates, with zoledronic acid as the preferred treatment, according to the National Comprehensive Cancer Network 8, 9
Pamidronate is an alternative option for treating hypercalcemia, as recommended by the European Society for Medical Oncology 9

For patients with primary hyperparathyroidism, monitoring may be appropriate for those not meeting surgical criteria, as stated by the Endocrine Society 10

For patients with severe renal impairment, denosumab is preferred over bisphosphonates, as recommended by the National Comprehensive Cancer Network 8

Perform periodic assessment of bone mineral density, as approximately 50% of individuals with hypercalcemia may have impaired bone mineral status, according to the American Academy of Pediatrics 6
For patients receiving bisphosphonate therapy, monitor for potential complications, including renal toxicity and post-treatment hypocalcemia, as advised by the European Society for Medical Oncology 9

Avoid administering Class IA, IC, or III antiarrhythmics in patients with hypercalcemia, as they may exacerbate cardiac toxicity, as warned by the American Heart Association 7
Avoid vitamin D supplementation in patients with hypercalcemia, as it may worsen the condition, according to the American Academy of Pediatrics 6